CNTB Connect Biopharma Holdings Ltd
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835268 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY382.0%
TTM net income YoY-37.9%
TTM EPS YoY-28.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,879.9%
Net margin-1,849.7%
FCF margin-1,504.2%
EBITDA margin-1,861.7%
Returns
ROE-201.5%
ROA-142.8%
ROIC (approx.)-834.2%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets56.6%
Debt / equity0.00x
Current ratio1.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-26.7%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $64,000 | $26.03M |
| R&D expense | $37.80M | $29.26M |
| SG&A expense | $20.34M | $19.23M |
| Operating income | -$58.07M | -$22.45M |
| Pretax income | -$55.28M | -$15.40M |
| Income tax | $197,000 | $223,000 |
| Net income | -$55.48M | -$15.63M |
| EBITDA | -$57.37M | -$21.79M |
| EPS (basic) | -1.00 | -0.28 |
| EPS (diluted) | -1.00 | -0.28 |
| Weighted avg. shares (diluted) | 55.66M | 55.21M |
| Balance sheet | ||
| Cash & equivalents | $38.34M | $78.23M |
| Short-term investments | $6.00M | $15.48M |
| Receivables | $13,000 | $789,000 |
| Current assets | $50.93M | $96.96M |
| PP&E, net | $3.81M | $4.05M |
| Intangibles | $45,000 | $53,000 |
| Total assets | $56.08M | $101.28M |
| Current liabilities | $13.61M | $8.46M |
| Total liabilities | $14.10M | $9.12M |
| Shareholders' equity | $41.98M | $92.17M |
| Shares outstanding | 56.44M | 55.35M |
| Cash flow statement | ||
| Operating cash flow | -$51.21M | -$23.61M |
| Capital expenditure | $434,000 | $750,000 |
| Free cash flow | -$51.64M | -$24.36M |
| Investing cash flow | $9.82M | -$3.45M |
| Financing cash flow | $1.09M | $227,000 |
| Depreciation & amortization | $704,000 | $660,000 |
| Stock-based compensation | $3.73M | $6.73M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.